BFM
CGEM icon

Boothbay Fund Management’s Cullinan Oncology CGEM Stock Holding History

Boothbay Fund Management’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$15.8M Sell
1,112,803
-124,240
-10% -$1.6M 0.21% 61
2025
Q4 		$12.8M Buy
+1,237,043
New +$11.2M 0.19% 97
2021
Q3 		– Sell
-39,113
Closed -$1.01M – 1919
2021
Q2 		$1.01M Buy
+39,113
New +$1.2M 0.03% 682

Other funds holding CGEM

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Boothbay Fund Management's CGEM Position: Q1 2026 in Review

Boothbay Fund Management reduced its Cullinan Oncology (CGEM) stake by 10% in Q1 2026, selling an estimated $1.6M and leaving 1,112,803 shares worth $15.8M. The position accounts for 0.21% of the portfolio, ranked #61.

Boothbay Fund Management first reported a position in CGEM in Q2 2021 and has held it in 3 quarters since. 174 funds tracked by Wall St. Rank hold CGEM as of Q1 2026.

  • Boothbay Fund Management held 1,112,803 shares of Cullinan Oncology worth $15.8M as of Q1 2026.
  • Boothbay Fund Management sold 124,240 Cullinan Oncology shares in Q1 2026, an estimated $1.6M.
  • Cullinan Oncology made up 0.21% of Boothbay Fund Management's portfolio in Q1 2026, its #61 holding.
  • Boothbay Fund Management first reported a position in Cullinan Oncology in Q2 2021 and has held it in 3 quarters since.
  • 174 funds tracked by Wall St. Rank held Cullinan Oncology as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.